Boehringer Ingelheim Bookmark and Share

ArticleDateSource
New Market Research Report: Boehringer Ingelheim GmbH: PharmaVitae Profile--Pharmaceutical - Moreover
Boehringer Ingelheim: a new commitment to diabetes--Pharmaceutical - Moreover
Hepregen Corporation Expands Agreement with Boehringer Ingelheim For...--PRWeb - Biotechnology
Boehringer Ingelheim and MacroGenics to Develop Antibody Therapeutics--Outsourcing - BioPharm
Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement --PRWeb - Biotechnology
Boehringer Ingelheim Corporation Presents First Phase 3 Data On Fixed-Dose Combination Of Tiotropium Plus Olodaterol In COPD May 21, 2014BioSpace - Breaking News
Boehringer Ingelheim Presents First Phase 3 Data on Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPDMay 21, 2014Pharma News - PR Newswire
Boehringer Ingelheim Corporation Facing 2,000+ U.S. Lawsuits Over Blood Thinner February 13, 2014BioSpace
FDA returns for look at risk of Boehringer Ingelheim's PradaxaJanuary 06, 2014FiercePharma
Boehringer Ingelheim Pharmaceuticals Inc. Earns CEO Cancer Gold Standard AccreditationDecember 13, 2013Pharma News - PharmiWeb
Boehringer Ingelheim Pharmaceuticals Inc. Earns CEO Cancer Gold Standard AccreditationDecember 13, 2013Pharma News - Business Wire
Boehringer Ingelheim Scores Perfect 100 in Human Rights Campaign’s Corporate Equality IndexDecember 09, 2013Pharma News - PharmiWeb
Boehringer Ingelheim Corporation Unit Taps Bank of America To Explore Sale Of Generics Business December 05, 2013BioSpace
Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes FederationDecember 02, 2013Medical Pharma - PR Newswire
Largest global survey investigating early Type 2 Diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes FederationDecember 02, 2013Pharma News - Business Wire
Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and overNovember 12, 2013Pharma News - Business Wire
MacroGenics to receive $9M from Boehringer Ingelheim in preclinical antibody pactNovember 11, 2013FierceBiotech Research
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Investigational Interferon-Free Regimen Demonstrates Undetectable Hepatitis C Virus in All Patients Reaching End of Treatment in Ongoing Phase 2 Trial October 08, 2013BioSpace - Breaking News
Boehringer Ingelheim plant has become a money pitOctober 07, 2013FiercePharma Manufacturing
Boehringer Ingelheim Shanghai plant tripling capacity September 30, 2013FiercePharma Manufacturing
Boehringer Ingelheim Corporation's Investigational Volasertib Receives FDA Breakthrough Therapy Designation September 17, 2013BioSpace
Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulationsSeptember 17, 2013Biotech News - Business Wire
Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulationsSeptember 17, 2013Pharma News - Business Wire
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designationSeptember 17, 2013Pharma News - PR Newswire
Boehringer Ingelheim Corporation. Pfizer Inc. Encounter Conflicting Data on Spiriva Safety September 11, 2013BioSpace
Boehringer Ingelheim Corporation Release: Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients With Moderate Asthma Severity September 10, 2013BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc.'s Landmark Tiospir ™ Trial Demonstrates Comparable Long-Term Safety of Tiotropium Delivered Via Respimat ® and Handihaler ® in COPD Patients September 09, 2013BioSpace - Breaking News
Boehringer Ingelheim Corporation's Olodaterol Effective in Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial September 09, 2013BioSpace - Breaking News
Boehringer Ingelheim Corporation to Cut Another 178 Jobs in France September 09, 2013BioSpace
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data September 03, 2013BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. Announces Plans to Expand Body of Evidence With Novel Cardiovascular Research Supporting Pradaxa® (dabigatran etexilate mesylate) September 03, 2013BioSpace - Breaking News
Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study September 03, 2013BioSpace
Boehringer Ingelheim Announces Plans to Expand Body of Evidence with Novel Cardiovascular Research Supporting Pradaxa® (dabigatran etexilate mesylate)September 03, 2013Clinical Trials - PR Newswire
FDA Accepts Boehringer Ingelheim Corporation's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism August 28, 2013BioSpace - Breaking News
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary EmbolismAugust 28, 2013Medical Pharma - PR Newswire
With Ben Venue cuts, Boehringer Ingelheim targets up to 640 U.S. jobsAugust 20, 2013FiercePharma
<b>Valneva</b> Announces a New EB66&#0174; Cell Line Research License Agreement With Boehringer Ingelheim Corporation July 16, 2013BioSpace - Breaking News
Boehringer Ingelheim Renews and Expands License to NextBio Research PlatformJuly 09, 2013Biotech News - PR Newswire
Evotec AG Rises on Boehringer Ingelheim Corporation Milestone Payment July 08, 2013BioSpace - Breaking News
Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar productJuly 08, 2013Biotech News - PR Newswire
Boehringer Ingelheim Corporation and Eli Lilly and Company Release: Results of New Meta-Analysis Regarding CV Events in Linagliptin Phase 3 Trials Presented at American Diabetes Association June 25, 2013BioSpace - Breaking News
Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations on Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions®June 11, 2013Pharma News - PR Newswire
Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions®June 11, 2013Pharma News - Business Wire
Boehringer Ingelheim Corporation's Investigational Faldaprevir+ Achieved Viral Cure in 88% of Treatment-Naive Hepatitis C Patients in Asia June 10, 2013BioSpace - Breaking News
Boehringer Ingelheim to Build New China PlantJune 07, 2013Inside Industry - Gen
Boehringer Ingelheim Corporation to Build Biopharma Facility in China, Creating 65 Jobs June 07, 2013BioSpace - Breaking News
Pharma giant Boehringer Ingelheim backs startup program Rock HealthJune 05, 2013FierceBiotech IT
Johnson & Johnson: We're Creaming Medivation, Inc., Boehringer Ingelheim Corporation, Bristol-Myers Squibb Company and Pfizer Inc. May 24, 2013BioSpace
Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, “Complications Combat”May 24, 2013Biotech News - Business Wire
Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, “Complications Combat”May 24, 2013Pharma News - Business Wire
Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a Range of Symptomatic Asthma Patients at ATS 2013May 21, 2013Clinical Trials - PR Newswire
Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseasesMay 08, 2013Pharma News - PharmiWeb
Boehringer Ingelheim announces results from one of its HCV Phase III trials: Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis CApril 23, 2013Pharma News - Business Wire
Boehringer Ingelheim Corporation Invests Undisclosed Amount Into Gene Therapy April 12, 2013BioSpace - Breaking News
Boehringer Ingelheim fuels gene therapy startup focused on eye diseasesApril 12, 2013FierceBiotech
European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Company's empagliflozin*, an investigational type 2 diabetes treatmentMarch 26, 2013Pharma News - PR Newswire
Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin*March 26, 2013Biotech News - Business Wire
Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin*March 26, 2013Pharma News - Business Wire
Humana and Boehringer Ingelheim Establish Partnership to Promote Population HealthMarch 25, 2013Pharma News - PharmiWeb
Boehringer Ingelheim Corporation and Eli Lilly and Company Submit New Drug Application to FDA for Empagliflozin, an Investigational Type 2 Diabetes Treatment March 25, 2013BioSpace - Breaking News
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with FaldaprevirMarch 04, 2013Biotech News - PR Newswire
Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis CMarch 04, 2013Biotech News - Business Wire
Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis CMarch 04, 2013Pharma News - Business Wire
Boehringer Ingelheim boosts social networking site for 'orphan' lung diseaseMarch 04, 2013FierceBiotech IT
FDA Advisory Committee Recommends Approval for Boehringer Ingelheim's Olodaterol for Maintenance Treatment of COPDJanuary 29, 2013Pharma News - PR Newswire
FDA Grants Priority Review to Boehringer Ingelheim Corporation???s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC January 16, 2013BioSpace - Breaking News
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozinJanuary 08, 2013Pharma News - PharmiWeb
National Institute for Clinical Excellence (NICE) Stroke Guidance Boost for Boehringer Ingelheim Corporation's Actilyse October 16, 2012BioSpace
Eli Lilly and Company and Boehringer Ingelheim Corporation Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue October 03, 2012BioSpace - Breaking News
Boehringer Ingelheim Expands Sales Force -- Adds 75 New PositionsSeptember 25, 2012Pharma News - PR Newswire
Data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance at EASD Annual MeetingSeptember 24, 2012Pharma News - PR Newswire
New data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance at EASD Annual MeetingSeptember 24, 2012Pharma News - Business Wire
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 CongressSeptember 20, 2012Biotech News - PR Newswire
Boehringer Ingelheim submits first oncology compound, afatinib* for European approvalSeptember 20, 2012Pharma News - Business Wire
FDA: Boehringer Ingelheim Pharmaceuticals, Inc.s' Parkinson's Drug May Have Possible Risk of Heart September 19, 2012BioSpace
Boehringer Ingelheim Launches Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray for Chronic Obstructive Pulmonary DiseaseSeptember 18, 2012Pharma News - PR Newswire
Boehringer Ingelheim closing 1 of 3 U.S. API plantsSeptember 17, 2012FiercePharma Manufacturing
Boehringer Ingelheim closing U.S. API plantSeptember 17, 2012FiercePharma Manufacturing
Boehringer Ingelheim debuts pharma game 'Syrum' on FacebookSeptember 17, 2012FierceBiotech IT
Boehringer Ingelheim Vetmedica, Inc. Invests $79 Million on Missouri Expansion; 115 New Jobs to be Created August 29, 2012BioSpace
FDA OKs Boehringer Ingelheim Corporation/Eli Lilly and Company's Tradjenta as Add-on to Insulin August 20, 2012BioSpace - Breaking News
Boehringer Ingelheim Corporation Achieves Growth in First Half of 2012 August 15, 2012BioSpace - Breaking News
Boehringer Ingelheim Corporation CEO Says Feels Heat From Euro Crisis July 24, 2012BioSpace
Boehringer Ingelheim Corporation Buys Funxional Therapeutics Ltd.'s Phase II Respiratory Drug Program July 23, 2012BioSpace - Breaking News
New Publication in Two-Year Study in Over 1,500 Patients Compares Boehringer Ingelheim Corporation and Eli Lilly and Company's Trajenta?? (Linagliptin) to the Commonly Prescribed Sulphonylurea Glimepiride June 28, 2012BioSpace - Breaking News
Boehringer Ingelheim Corporation Release: First Study to Evaluate Alternative to Warfarin for Mechanical Heart Valve Patients Launched with Pradaxa?? (dabigatran etexilate) June 20, 2012BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. Release: RE-LY Sub-Analysis Suggests Pradaxa?? (Dabigatran Etexilate Mesylate) Associated With Similar Bleeding Rates And Thromboembolic Complications In Surgery Versus Warfarin June 18, 2012BioSpace - Breaking News
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. Present Data at the 72nd Boehringer Ingelheim Pharmaceuticals, Inc. Scientific Sessions?? from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine June 12, 2012BioSpace - Breaking News
Polyphor Signs MacroFinder?? Collaboration With Boehringer Ingelheim Corporation June 12, 2012BioSpace - Breaking News
Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin GlargineJune 11, 2012Pharma News - PR Newswire
Boehringer Ingelheim Corporation Release: New Linagliptin Phase III Data Demonstrate Significant Reductions in Blood Glucose With No Additional Risk of Hypoglycaemia When Combined With Insulin in Patients With Type 2 Diabetes June 11, 2012BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd Scientific Sessions®June 09, 2012Pharma News - PR Newswire
Evotec AG Receives EUR 4 Million Milestone Payment from Boehringer Ingelheim Corporation June 05, 2012BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company to Feature 30 Presentations on Type 1 and Type 2 Diabetes at the 72nd American Diabetes Association Scientific Sessions®June 05, 2012Pharma News - PR Newswire
Boehringer Ingelheim Corporation and Eli Lilly and Company Release: Jentadueto??? (Linagliptin/Metformin Hydrochloride) Tablets Recommended for Approval in the Treatment of Adults with Type 2 Diabetes in Europe May 25, 2012BioSpace - Breaking News
European Medicines Evaluation Agency Confirms Boehringer Ingelheim Corporation's Pradaxa Benefits, But Wants Clearer Guidance May 25, 2012BioSpace - Breaking News
Breathe Deeply: Safety Concerns Over Boehringer Ingelheim Corporation's Spiriva May 24, 2012BioSpace
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent AsthmaMay 22, 2012Biotech News - PR Newswire
Boehringer Ingelheim Announces Positive Phase II Results for Once-Daily Tiotropium in AsthmaMay 22, 2012Pharma News - Business Wire
Results of Phase II Study of Boehringer Ingelheim's Investigational Bronchodilator for COPD Presented at 2012 ATS International ConferenceMay 21, 2012Pharma News - PharmiWeb
The Incredible Shrinking Salesforce? Not Everywhere - Big Drugmakers Like Boehringer Ingelheim Corporation, Novo Nordisk A/S are Still Hiring! May 18, 2012BioSpace
Boehringer Ingelheim Corporation Reports Convincing Data for Lung Cancer Therapy May 17, 2012BioSpace
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012May 16, 2012Pharma News - PR Newswire
New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Corporation Respiratory Research Pipeline May 08, 2012BioSpace - Breaking News
New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research PipelineMay 08, 2012Pharma News - PR Newswire
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial FibrillationMay 03, 2012Pharma News - PR Newswire
Boehringer Ingelheim Calls for Proposals on Equine Pigeon FeverApril 30, 2012Medical Pharma - PR Newswire
Ablynx Release: Nanobody for Alzheimer's Disease From the Alliance With Boehringer Ingelheim Corporation Moves Closer Towards Phase I Clinical Trials April 25, 2012BioSpace - Breaking News
Boehringer Ingelheim Corporation's 2011 Profit Jumps 66 Percent April 25, 2012BioSpace - Breaking News
Nanobody for Alzheimer's Disease From The Alliance With Boehringer Ingelheim Moves Closer Towards Phase I Clinical TrialsApril 25, 2012Marketwire - Pharma and Biotech
Boehringer Ingelheim Standardizes All Prescription Medicine Commercial Teams Worldwide on Cloud-Based, Veeva CRM and iRepApril 25, 2012Pharma News - PR Newswire
Boehringer Ingelheim uniformiza a nivel mundial todos los equipos comerciales de venta de medicamentosApril 25, 2012Biotech News - PR Newswire
Il gruppo Boehringer Ingelheim decide di standardizzare a livello mondiale tutti i team commerciali operanti nel settore dei farmaci da prescrizione con le soluzioni cloud-based Veeva CRM e iRepApril 25, 2012Biotech News - PR Newswire
Boehringer Ingelheim standardisiert weltweit sämtliche für verschreibungspflichtige Medikamente zuständigen Vertriebsabteilungen auf Cloud-basiertes Veeva CRM und iRepApril 25, 2012Biotech News - PR Newswire
Boehringer Ingelheim Corporation Hepatitis C Drugs Cured 82% in Phase II Trial April 19, 2012BioSpace - Breaking News
Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)April 19, 2012Pharma News - PR Newswire
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa(R) (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY?? Trial April 18, 2012BioSpace - Breaking News
Boehringer Ingelheim Corporation Release: More Time, More Lives: New Authorisation to Make Life-saving Treatment Available to Ischaemic Stroke Patients Presenting Within 4.5 Hrs After the Onset of Stroke Symptoms April 16, 2012BioSpace - Breaking News
Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License AgreementApril 04, 2012Pharma News - PR Newswire
Boehringer Ingelheim Corporation Cuts Pradaxa Price by 13 Percent in the UK March 29, 2012BioSpace - Breaking News
Ablynx Announces a EUR6.6 Million Extension of Its Strategic Nanobody Alliance With Boehringer Ingelheim Corporation March 21, 2012BioSpace
Boehringer Ingelheim Corporation's Pradaxa Wins UK Agency's Backing in Stroke March 15, 2012BioSpace - Breaking News
Boehringer Ingelheim Corporation Eyes Pfizer Animal Health Business March 12, 2012BioSpace
Troubled Boehringer Ingelheim Corporation Unit, Bedford Laboratories Recalls Leukemia Medicine March 09, 2012BioSpace
Boehringer Ingelheim expands capabilitiesMarch 09, 2012Contract Pharma
Boehringer Ingelheim expands capabilities in biopharmaceutical process scienceMarch 09, 2012Pharma News - PharmiWeb
Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmaciesMarch 07, 2012Biotech News - PR Newswire
Boehringer Ingelheim spends €17M on expansion in Germany, ViennaMarch 06, 2012FiercePharma Manufacturing
Boehringer Ingelheim spends €17 million on expansion in Germany, ViennaMarch 06, 2012FiercePharma Manufacturing
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal AntibodiesFebruary 21, 2012Medical Pharma - PR Newswire
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product supplyFebruary 10, 2012Pharma News - PharmiWeb
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Study Finds No Drug-Drug Interaction Between Aggrenox(R) (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI February 06, 2012BioSpace - Breaking News
Ablynx Receives Another EUR $5 Million Milestone as Boehringer Ingelheim Corporation Selects Nanobody Candidate for Pre-Clinical Development February 01, 2012BioSpace - Breaking News
Ablynx Receives Another Milestone as Boehringer Ingelheim Selects Nanobody Candidate for Pre-Clinical DevelopmentFebruary 01, 2012Marketwire - Pharma and Biotech
FDA Approves Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company's Diabetics Therapy Jentadueto??? January 31, 2012BioSpace
Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supplyJanuary 27, 2012Pharma News - PharmiWeb
Boehringer Ingelheim Corporation Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib* January 26, 2012BioSpace - Breaking News
Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*January 26, 2012Pharma News - Business Wire
Boehringer Ingelheim Prolongates Drug Discovery Collaboration with PriaxonJanuary 24, 2012b3c newswire
CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.January 17, 2012Biotech News - PR Newswire
Boehringer Ingelheim Corporation's Pradaxa Increases Risk of Heart Attack, Study Shows January 10, 2012BioSpace
FORMA Therapeutics, Inc. Cuts $815 Million Deal With Boehringer Ingelheim Corporation to Discover Cancer Drugs January 05, 2012BioSpace
Forma Cuts $65M Deal With Boehringer Ingelheim to Discover Cancer DrugsJanuary 05, 2012Xconomy Life Sciences
FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology DrugsJanuary 05, 2012Pharma News - Business Wire
<b>PPS</b> Admits Falsifying Record for a 2007 Trial of Boehringer Ingelheim Corporation's 'Female Viagra' January 03, 2012BioSpace
MacroGenics, Inc. Receives Milestone Payment as Part of Its Global DART??? Alliance With Boehringer Ingelheim Corporation December 20, 2011BioSpace - Breaking News
AbGenomics Corporation Regains Global Rights to AbGn-168H from Boehringer Ingelheim Corporation December 19, 2011BioSpace - Breaking News
Boehringer Ingelheim Corporation Sets $91 Million Shanghai Expansion December 15, 2011BioSpace
Boehringer Ingelheim significantly expands its supply center for ChinaDecember 14, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Corporation Completes Patient Entry for Phase III Ttrial Programme in Hepatitis C December 09, 2011BioSpace - Breaking News
Boehringer Ingelheim completes patient entry for Phase III trial programme in Hepatitis CDecember 09, 2011FDA News - Business Wire
FDA: Boehringer Ingelheim Corporation's Pradaxa Benefit Outweighs Bleeding Risk December 08, 2011BioSpace
Boehringer Ingelheim GmbH,<Lilly Diabetes</b> Release: Linagliptin Demonstrates Meaningful Improvement in Glycaemic Control in Initial Combination Therapy with metformin December 08, 2011BioSpace - Breaking News
Numerate and Boehringer Ingelheim (Canada) Form Research Collaboration Based on in silico Drug Design TechnologyDecember 06, 2011Pharma News - Business Wire
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim Corporation Announce Manufacturing Agreement for Ficlatuzumab December 01, 2011BioSpace - Breaking News
AVEO Pharmaceuticals and Boehringer Ingelheim Announce Manufacturing Agreement for FiclatuzumabDecember 01, 2011Pharma News - Business Wire
Boehringer Ingelheim Builds API Facility in U.S.November 28, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Corporation's Pradaxa?? Awarded Prix Galien for Most Innovative Product in CanadaNovember 23, 2011Pharmaceutical - Moreover
<b>EU</b> Recalls Cancer Meds Made by Boehringer Ingelheim Corporation Unit November 23, 2011BioSpace
<b>EU</b> Backs Boehringer Ingelheim Corporation's Pradaxa Bloodthinner, Despite Deaths November 18, 2011BioSpace - Breaking News
Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" CompetitionNovember 15, 2011Medical Pharma - PR Newswire
Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion ProjectsNovember 15, 2011Biotech News - PR Newswire
Boehringer Ingelheim Corporation to Build $65 Million US Research Facility November 15, 2011BioSpace
Boehringer Ingelheim begins R&D facility construction in RidgefieldNovember 15, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Subanalyses of RE-LY(R) Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation November 14, 2011BioSpace - Breaking News
Boehringer Ingelheim Corporation Says About 260 Deaths Related to Pradaxa November 14, 2011BioSpace
NCCN Receives $2 Million in Oncology Research Funding from Boehringer Ingelheim to Investigate Afatinib in Solid TumorsNovember 10, 2011Pharma News - Business Wire
Boehringer Ingelheim Vetmedica, Inc. Release: Obesity and Diabetes are Increasing in Cats November 09, 2011BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types November 08, 2011BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. Release: BI 201335 Demonstrates Potential toShorten HCV Treatment Duration While Achieving High Sustained Virological Response Rates in Difficult to Treat Patients November 08, 2011BioSpace - Breaking News
Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLDNovember 07, 2011Pharma News - PR Newswire
Boehringer Ingelheim Corporation Says About 50 Deaths Related to Pradaxa November 03, 2011BioSpace
Boehringer Ingelheim Corporation's Pradaxa Wins UK Backing for Stroke Prevention November 01, 2011BioSpace - Breaking News
Nippon Boehringer Ingelheim and Yamanouchi Launch "MICARDIS Capsule 20mg and 40mg," a New Long Acting Angiotensin II Receptor BlockerOctober 30, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Implements Additional Guidance Supporting Appropriate Use of Pradaxa® (dabigatran etexilate) in EuropeOctober 27, 2011Pharma News - Business Wire
Patheon, Boehringer Ingelheim sign 3-year $18 mn development agreementOctober 24, 2011Pharmaceutical - Moreover
Boehringer Ingelheim in Consumer Health (World)October 21, 2011Pharmaceutical - Moreover
Patheon (PTI.TO) Signs Three Year $18 Million Development Agreement with Boehringer Ingelheim CorporationOctober 21, 2011Pharmaceutical - Moreover
New Boehringer Ingelheim Hepatitis C Data to Be Presented at AASLDOctober 21, 2011Pharma News - Business Wire
Patheon Signs Three Year $18 Million Development Agreement with Boehringer Ingelheim Corporation October 20, 2011BioSpace
$18 Million Development Agreement with Boehringer Ingelheim Announced by PatheonOctober 20, 2011Pharmaceutical - Moreover
Patheon signs three year $18 million development agreement with Boehringer Ingelheim (CNW)October 20, 2011Pharmaceutical - Moreover
Pharmaceutical giant Boehringer Ingelheim hands Pegasus animal drug briefOctober 11, 2011Pharmaceutical - Moreover
FDA Approves Boehringer Ingelheim Pharmaceuticals, Inc.'s Combivent(R) Respimat(R) (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease October 10, 2011BioSpace
Gilead y Boehringer Ingelheim firman acuerdo de licencia para nuevos inhibidores de la integrasa no catalíticos para el VIHOctober 07, 2011Pharma News - Business Wire
Gilead en Boehringer Ingelheim ondertekenen licentieovereenkomst voor nieuwe HIV niet-katalytische integraseremmersOctober 06, 2011Pharma News - Business Wire
Gilead und Boehringer Ingelheim unterzeichnen Lizenzvereinbarung für neuartige nicht-katalytische Integraseinhibitoren gegen HIVOctober 06, 2011Pharma News - Business Wire
Gilead et Boehringer Ingelheim signent un accord de licence portant sur les nouveaux inhibiteurs de l’intégrase du VIH non catalytiquesOctober 06, 2011Pharma News - Business Wire
Gilead e Boehringer Ingelheim sottoscrivono un contratto di licenza per dei nuovi inibitori del sito non catalitico dell’integrasi per l’HIVOctober 06, 2011Pharma News - Business Wire
Gilead Sciences, Inc. and Boehringer Ingelheim Corporation Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors October 06, 2011BioSpace
Gilead in licensing deal with Boehringer Ingelheim October 06, 2011Health News - BizJournals.com
Boehringer Ingelheim - Top 10 Standout CMOsOctober 06, 2011FiercePharma Manufacturing
Gilead strikes licensing deal with Boehringer Ingelheim on new HIV drugOctober 05, 2011Health News - BizJournals.com
Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase InhibitorsOctober 05, 2011Pharma News - Business Wire
Boehringer Ingelheim India and Eli Lilly India expand strategic diabetes allianceOctober 03, 2011Pharmaceutical - Moreover
Novartis AG' Onbrez Beats Boehringer Ingelheim Corporation/Pfizer Inc.'s Spiriva for COPD Quality of Life October 03, 2011BioSpace
New Data from Boehringer Ingelheim HCV Portfolio to be Presented at AASLDOctober 03, 2011Pharma News - PR Newswire
Boehringer Ingelheim Corporation Expands its Business with Biosimilars September 27, 2011BioSpace
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Study Published in The New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis September 22, 2011BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis September 22, 2011BioSpace - Breaking News
Boehringer Ingelheim Corporation Enrolls First Patient in Phase III Program for New Once-Daily Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD September 21, 2011BioSpace - Breaking News
Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPDSeptember 21, 2011Pharma News - Business Wire
Boehringer Ingelheim Corporation Release: New Data for Once-Daily Linagliptin Show Durable Efficacy Over Two Years September 16, 2011BioSpace - Breaking News
Boehringer Ingelheim Corporation Sketches Out $3September 15, 2011Biotechnology - Moreover
Boehringer Ingelheim Corporation Sketches Out $382 Million Expansion Plan September 14, 2011BioSpace
Boehringer Ingelheim Corporation Expands Connecticut Facility; Looking to Hire September 14, 2011BioSpace
Boehringer Ingelheim wins Frost & Sullivan Award for Biopharmaceutical Contract ManufacturingSeptember 13, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Corporation's Pradaxa Causes a Side Effect Flap in New Zealand September 12, 2011BioSpace
Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of DiabetesSeptember 07, 2011Clinical Trials - PR Newswire
Boehringer Ingelheim Corporation and Eli Lilly and Company Delay Trajenta Launch in Germany September 06, 2011BioSpace
Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound AfatinibSeptember 06, 2011Biotech News - PR Newswire
Evotec AG Receives Pre-Clinical Milestone Payment as Part of Its Discovery Alliance With Boehringer Ingelheim Corporation August 18, 2011BioSpace - Breaking News
Deaths Prompt Revisions in Japanese Precautions for Boehringer Ingelheim Corporation's Prazaxa August 15, 2011BioSpace
Boehringer Ingelheim Licenses ProBioGen's Novel GlymaxX TechnologyAugust 10, 2011b3c newswire
Boehringer Ingelheim Gets European Approval For PradaxaAugust 04, 2011Pharmaceutical - Moreover
AHF: Victory! Boehringer Ingelheim to Increase AIDS Drug Program RebatesAugust 03, 2011Pharma News - Business Wire
Boehringer Ingelheim Launches Pradaxa For Stroke Prevention TreatmentAugust 02, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Vetmedica, Inc. Plant Closure Slashes 100 Jobs July 14, 2011BioSpace - Breaking News
Boehringer Ingelheim Corporation Must Pay Overtime to Sales Rep: Judge July 14, 2011BioSpace - Breaking News
Boehringer Ingelheim Vetmedica, Inc. Plant Closure Slashes100 Jobs July 14, 2011BioSpace - Breaking News
Boehringer Ingelheim Pitches Big-Budget Global Pharma BriefsJuly 10, 2011Pharmaceutical - Moreover
EU drops Boehringer Ingelheim patent probeJuly 07, 2011Pharmaceutical - Moreover
Antitrust Officials Close Boehringer Ingelheim Corporation Probe July 07, 2011BioSpace
Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" CompetitionJuly 06, 2011Pharma News - PR Newswire
Boehringer Ingelheim y Ashoka Changemakers lanzan el desafío "Más salud: mejorando la vida de individuos, familias y comunidades"July 06, 2011Pharma News - PR Newswire
Boehringer Ingelheim e Changemakers da Ashoka lançam o desafio "Mais saúde: melhorando a vida de pessoas, famílias e comunidades"July 06, 2011Pharma News - PR Newswire
Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" CompetitionJuly 06, 2011Pharma News - PharmiWeb
Boehringer Ingelheim und die Changemakers von Ashoka rufen den Wettbewerb "Making More Health" ins LebenJuly 06, 2011Pharma News - PR Newswire
Boehringer Ingelheim et Ashoka Changemakers lancent le défi « Meilleure Santé : Améliorer le bien-être des Individus, des Familles et des Communautés »July 06, 2011Pharma News - PR Newswire
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Phase III Data and Pooled Analysis for Linagliptin Show Improved Blood Sugar Control in Adults With Type 2 Diabetes When Used Alone and With Metformin June 27, 2011BioSpace - Breaking News
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe June 24, 2011BioSpace - Breaking News
Ashoka and Boehringer Ingelheim initiative to promote healthJune 24, 2011Pharmaceutical - Moreover
Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"June 22, 2011Pharma News - PR Newswire
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company to Feature Type 2 Diabetes Research in More Than 25 Presentations at the 71st American Diabetes Association Scientific Sessions June 20, 2011BioSpace - Breaking News
Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in More Than 25 Presentations at the 71st American Diabetes Association Scientific SessionsJune 20, 2011Clinical Trials - PR Newswire
Zealand Pharma and Boehringer Ingelheim Corporation Enter Into a License and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity in Deal Worth $530 Million June 16, 2011BioSpace
Zealand Pharma and Boehringer Ingelheim Corporation Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity June 16, 2011BioSpace - Breaking News
Zealand Pharma and Boehringer Ingelheim Corporation Enter Into a License and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity in Deal Worth 376M Euros ($530M) June 16, 2011BioSpace
Collaboration Gives Boehringer Ingelheim Rights to Zealand’s Type 2 Diabetes CandidateJune 16, 2011Inside Industry - Gen
Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and ObesityJune 16, 2011Biotech News - PR Newswire
Boehringer Ingelheim and Lilly's New Type 2 Diabetes Treatment Tradjenta™ (Linagliptin) Tablets for Adults Now Available in U.S. PharmaciesJune 15, 2011Pharma News - PR Newswire
Research and Markets: Drug Delivery Devices Market Outlook in New Zealand to 2017 - Key Players Include GlaxoSmithKline plc, Boehringer Ingelheim GmbH & MoreMay 31, 2011Pharma News - Business Wire
Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLCMay 25, 2011Pharma News - PR Newswire
New Market Report Now Available: Boehringer Ingelheim GmbH: PharmaVitae ProfileMay 20, 2011Pharmaceutical - Moreover
FDA Approves Boehringer Ingelheim Corporation, Eli Lilly and Company's Tradjenta Tablets for the Treatment of Type 2 Diabetes May 03, 2011BioSpace
Boehringer Ingelheim begins Phase 3 HCV trialApril 27, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Corporation Announces Enrollment of First Patient in Phase 3 Trial for Lead Hepatitis C Compound April 26, 2011BioSpace - Breaking News
Boehringer Ingelheim Announces Enrollment of First Patient in Phase 3 Trial for Lead Hepatitis C CompoundApril 26, 2011Biotech News - PR Newswire
Boehringer Ingelheim Corporation FY Profit Slumps 50 Pct, Hit by Generics April 05, 2011BioSpace
FDA Approves Boehringer Ingelheim Corporation's One-Pill, Once-Daily Viramune(R) XR (nevirapine) Extended-Release Tablets for Use in Combination With Other Antiretroviral Agents for Treatment of HIV-1 Infection in Adults April 05, 2011BioSpace
Boehringer Ingelheim Corporation''s Lead Hepatitis C Compound Moves into Phase 3 - the First Within the BI HCV Portfolio April 04, 2011BioSpace - Breaking News
Boehringer Ingelheim Lands Good News on HCV TreatmentApril 02, 2011Pharmaceutical - Moreover
Boehringer Ingelheim's Lead Hepatitis C Compound Moves into Phase 3 - the First Within the BI HCV PortfolioApril 02, 2011Clinical Trials - PR Newswire
Boehringer Ingelheim lands good news on HCV treatmentApril 01, 2011Pharmaceutical - Moreover
Sustained Viral Response Achieved in 83% of Hepatitis C Infected Patients with New HCV Protease Inhibitor from Boehringer Ingelheim GmbH April 01, 2011BioSpace - Breaking News
Positive Phase 2 Results Reported with Boehringer Ingelheim Corporation's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients April 01, 2011BioSpace
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated PatientsApril 01, 2011Biotech News - PR Newswire
Boehringer Ingelheim finaliza aquisição da unidade de Fremont da Amgen nos EUAMarch 25, 2011Biotech News - PR Newswire
Boehringer Ingelheim finaliza la adquisición de la planta de Amgen en Fremont, en los Estados UnidosMarch 25, 2011Biotech News - PR Newswire
Boehringer Ingelheim Corporation Finalizes Acquisition of Amgen's Fremont Facility in the USA March 25, 2011BioSpace - Breaking News
Boehringer Ingelheim Selects China Supply Chain ServicesMarch 25, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Finalizes Acquisition of Amgen's Fremont Facility in the USAMarch 24, 2011Medical Pharma - PR Newswire
Kansas City Area Development Council’s Parman leaves for Boehringer Ingelheim VetmedicaMarch 21, 2011Health News - BizJournals.com
Pharmaceutical and Biomedical Analysis: New Findings in Pharmaceutical and Biomedical Analysis Described from Boehringer Ingelheim GmbHMarch 20, 2011Pharmaceutical - Moreover
New Hepatitis C Data from Boehringer Ingelheim HCV Portfolio to Be Presented at EASLMarch 14, 2011Pharma News - Business Wire
Boehringer Ingelheim Vetmedica will start new administrative buildingMarch 07, 2011Health News - BizJournals.com
Evonik finalizes acquisition of Boehringer Ingelheim's RESOMER businessMarch 03, 2011Pharmaceutical - Moreover
Boehringer Ingelheim taps Campaigns & Grey for Dulcolax regional campaignMarch 03, 2011Pharmaceutical - Moreover
Light Metals: New Light Metals Data Have Been Reported by Scientists at Boehringer Ingelheim GmbHFebruary 20, 2011Pharmaceutical - Moreover
PfÄnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the use of PfÄnex Expression Technologyâ¢February 16, 2011Pharmaceutical - Moreover
Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression TechnologyFebruary 16, 2011Pharmaceutical - Moreover
Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic AgreementFebruary 16, 2011Pharmaceutical - Moreover
Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technologyâ¢February 15, 2011Pharmaceutical - Moreover
Pfenex Inc. and Boehringer Ingelheim Corporation Announce Non-Exclusive Strategic Agreement for the use of Pfenex Expression Technology(TM) February 15, 2011BioSpace
Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™February 15, 2011Biotech News - PR Newswire
The World Heart Federation, sanofi-aventis and Boehringer Ingelheim Announce Collaboration on Worldwide AF Awareness CampaignFebruary 15, 2011Medical Pharma - PR Newswire
Elan and Boehringer Ingelheim in development dealFebruary 09, 2011Pharmaceutical - Moreover
Elan, Boehringer Ingelheim Inks Development And Manufacturing PactFebruary 09, 2011Health News - Fox Business
Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement for Elan’s Antibody-Based Therapeutics PipelineFebruary 09, 2011Pharma News - PharmiWeb
Boehringer Ingelheim to Purchase Amgen's Fremont (USA) FacilityJanuary 31, 2011Pharma News - PR Newswire
Recently released market study: Boehringer Ingelheim GmbH: PharmaVitae ProfileJanuary 26, 2011Pharmaceutical - Moreover
MorphoSys Announces Clinical Milestone within Boehringer Ingelheim AllianceJanuary 24, 2011Marketwire - Pharma and Biotech
Boehringer Ingelheim Corporation's PRAZAXA(R) (dabigatran etexilate) Approved in Japan for Stroke Prevention in Atrial Fibrillation January 21, 2011BioSpace - Breaking News
Boehringer Ingelheim: Japan Oks Prazaxa For Stroke PreventionJanuary 21, 2011Health News - Fox Business
AIDS-Arzneimittelhersteller Boehringer Ingelheim weigert sich, einkommensschwachen Patienten besseren Therapiezugang zu verschaffenJanuary 21, 2011Pharma News - Business Wire
Boehringer Ingelheim: advances in oncology and diabetesJanuary 20, 2011Pharmaceutical - Moreover
AIDS Drug Maker Boehringer Ingelheim Refuses to Increase Access for Low-Income PatientsJanuary 19, 2011Pharma News - Business Wire
Boehringer Ingelheim to Purchase Amgen’s Fremont Manufacturing SiteJanuary 19, 2011Inside Industry - Gen
Boehringer Ingelheim Corporation to Purchase Amgen's Fremont (California) Facility January 19, 2011BioSpace
Boehringer Ingelheim To Acquire Amgen's Fremont California Facility - UpdateJanuary 19, 2011Biotechnology - Moreover
Boehringer Ingelheim to Purchase Amgen's Fremont (California) FacilityJanuary 18, 2011Biotech News - PR Newswire
Week of Jan. 10, 2011: Company and People Notes: Eli Lilly and Boehringer Ingelheim Form Diabetes Pact; DSM Pharmaceutical Products Names President and CEO; and more.January 18, 2011Pharmaceutical - Moreover
Week of Jan. 10, 2011: Company and People Notes: Eli Lilly and Boehringer Ingelheim Form Diabetes Pact; DSM Pharmaceutical Products Names President and CEO; and more.January 18, 2011Pharmaceutical - Moreover
Evonik agrees on purchase of Boehringer Ingelheim's polymer portfolioJanuary 17, 2011Pharmaceutical - Moreover
Boehringer Ingelheim to sell Resomer business to EvonikJanuary 17, 2011Pharmaceutical - Moreover
Evonik and Boehringer Ingelheim Have Signed An Agreement on the Sale of the Resomer Business to EvonikJanuary 14, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Agrees To Sell Resomer To EvonikJanuary 14, 2011Health News - Fox Business
Company and People Notes: Eli Lilly and Boehringer Ingelheim Form Diabetes Pact; DSM Pharmaceutical Products Names President and CEO; and more.January 13, 2011Pharmaceutical - Moreover
Boehringer Ingelheim and Eli Lilly join forces to develop new diabetes treatmentsJanuary 12, 2011Pharmaceutical - Moreover
Company and People Notes: Eli Lilly and Boehringer Ingelheim Form Diabetes Pact; DSM Pharmaceutical Products Names President and CEO; and more.January 12, 2011Pharmaceutical - Moreover
Eli Lilly and Company and Boehringer Ingelheim Corporation Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide; to Get 300M Euro; up to a Total of 625M Euro January 11, 2011BioSpace
Lilly, Boehringer Ingelheim In Diabetes Alliance January 11, 2011Contract Pharma
Eli Lilly and Company and Boehringer Ingelheim Corporation Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide; to Get 300 M Euro; up to a total of 625M Euro January 11, 2011BioSpace
Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients WorldwideJanuary 11, 2011Pharma News - PR Newswire
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients WorldwideJanuary 11, 2011Pharma News - Business Wire
Hepregen Corporation Expands Agreement with Boehringer Ingelheim for the Adoption of HepatoPacJanuary 06, 2011Pharmaceutical - Moreover
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion January 05, 2011BioSpace - Breaking News
Dosage Forms: Study data from Boehringer Ingelheim GmbH update understanding of dosage formsJanuary 02, 2011Pharmaceutical - Moreover
Orexo gets $8.6 million milestone in Boehringer Ingelheim collaborationDecember 17, 2010Pharmaceutical - Moreover
Boehringer Ingelheim and Orexo report progress in their pain and inflammatory diseases collaborationDecember 17, 2010Pharmaceutical - Moreover
Orexo AB and Boehringer Ingelheim Corporation Report Progress in Their Pain and Inflammatory Diseases Collaboration; Triggers EUR6.5 Million Milestone Payment to OrexoDecember 16, 2010Pharmaceutical - Moreover
Orexo AB and Boehringer Ingelheim Corporation Report Progress in Their Pain and Inflammatory Diseases Collaboration; Triggers EUR6.5 Million Milestone Payment to December 16, 2010BioSpace
Orexo and Boehringer Ingelheim Report Progress in Their Pain and Inflammatory ...December 16, 2010Pharmaceutical - Moreover
Orexo and Boehringer Ingelheim Report Progress in Their Pain and Inflammatory Diseases CollaborationDecember 16, 2010Pharma News - Business Wire
Boehringer Ingelheim: Study Suggest Benefit From AfatinibDecember 09, 2010Health News - Fox Business
Boehringer Ingelheim Corporation New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations December 09, 2010BioSpace - Breaking News
Ablynx Announces Nanobody Candidate Selected by Boehringer Ingelheim Corporation for Development; Will Receive EUR 5 Million Payment December 08, 2010BioSpace
Nanobody Candidate Selected by Boehringer Ingelheim for DevelopmentDecember 08, 2010Marketwire - Pharma and Biotech
Boehringer Ingelheim Corporation Initiates Phase III Clinical Trial With Afatinib in Advanced Breast Cancer December 08, 2010BioSpace - Breaking News
Boehringer Ingelheim Initiates Phase III Clinical Trial With Afatinib in Advanced Breast CancerDecember 08, 2010Pharma News - PR Newswire
Boehringer Ingelheim casts f-star in potential €1.3 billion antibody blockbuster roleNovember 22, 2010Pharmaceutical - Moreover
f-Star and Boehringer Ingelheim Corporation to Collaborate in Discovery and Development of Therapeutic Antibodies; Deal Could be Worth Over 1.2 Billion Euros November 22, 2010BioSpace
f-star and Boehringer Ingelheim to Collaborate in Discovery and Development of Therapeutic AntibodiesNovember 22, 2010Pharma News - Business Wire
Boehringer Ingelheim RCV and Fresenius Kabi successfully coupled HES to a therapeutic protein in an industrial scale applying Fresenius Kabi?s HESylation? TechnologyNovember 18, 2010Pharmaceutical - Moreover
Boehringer Ingelheim IPF investigational compound BIBF1120 shows efficacy in Phase II studyNovember 17, 2010Pharmaceutical - Moreover
Boehringer Ingelheim & Fresenius Kabi collaborate for HESylated pharmaceutical productionNovember 15, 2010Pharmaceutical - Moreover
Ablynx Receives Further Milestone Payments of EUR3 Million as Part of Its Strategic Alliance With Boehringer Ingelheim Corporation November 12, 2010BioSpace - Breaking News
Research and Markets: Gain a Comprehensive Picture of a Company's Strategic Direction with This Latest IMS Company Profile on Boehringer Ingelheim for 2010November 12, 2010Pharma News - Business Wire
Boehringer Ingelheim RCV and Fresenius Kabi successfully coupled HES to a therapeutic protein in an industrial scale applying Fresenius Kabi’s HESylation® TechnologyNovember 11, 2010Pharmaceutical - Moreover
Boehringer Ingelheim GmbH's Drug Lowers Bleeding Risk in Those Who Had Stroke November 08, 2010BioSpace - Breaking News
Boehringer Ingelheim's Pradaxa Available in U.S. Pharmacies Starting Wednesday, November 3November 01, 2010Pharma News - PR Newswire
Results of Boehringer Ingelheim Corporation Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon November 01, 2010BioSpace - Breaking News
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated InterferonOctober 30, 2010Pharma News - PR Newswire
Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Shows Rapid Viral Response without Use of Pegylated InterferonOctober 30, 2010Pharma News - Business Wire
Boehringer Ingelheim GmbH Release: PRADAX(TM) (Dabigatran Etexilate) Gains Approval in Canada for Stroke Prevention in Atrial Fibrillation October 27, 2010BioSpace - Breaking News
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody TherapeuticsOctober 26, 2010Biotech News - PR Newswire
Bayer AG (BAY.F) and Johnson & Johnson (JNJ) Rival Boehringer Ingelheim Corporation Prices Blood Pill At $6.75; Setting PrecedentOctober 26, 2010Biotechnology - Moreover
Bayer AG and Johnson & Johnson Rival Boehringer Ingelheim Corporation Prices Blood Pill At $6.75; Setting Precedent October 26, 2010BioSpace - Breaking News
Boehringer Ingelheim Corporation and MacroGenics, Inc. Announce Global Alliance to Discover, Develop and Commercialize DART-Based Antibody Therapeutics; Expects to Receive At Least $60 Million and Could be up to $210 Million October 26, 2010BioSpace
Boehringer Ingelheim GmbH's Dabigatran: The Case of the Missing 110-mg Dose, Brigham and Women's Hospital Study October 22, 2010BioSpace
FDA Approves Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation October 20, 2010BioSpace
Boehringer Ingelheim junto a la Comisión Latina sobre el SIDA lanzan MenteCuerpoHAART.com para celebrar el Día Nacional de la Prevención del Sida en LatinosOctober 14, 2010Pharma News - PR Newswire
Boehringer Ingelheim and the Latino Commission on AIDS Launch MenteCuerpoHAART.com on National Latino AIDS Awareness DayOctober 14, 2010Pharma News - PR Newswire
European Medicines Evaluation Agency Approves Boehringer Ingelheim Corporation's TWYNSTA(R) a New Single Pill Combination that Delivers Powerful and Consistent Blood Pressure Reductions Throughout 24 Hours October 12, 2010BioSpace - Breaking News
Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License AgreementOctober 12, 2010Pharma News - Business Wire
Boehringer Ingelheim GmbH Ends Female Desire Drug Flibanserin Development After FDA's Safety Query October 08, 2010BioSpace
Ablynx Receives Further Milestone Payments Of Eur3 Million ($4.2 Million) As Part Of Its Strategic Alliance With Boehringer Ingelheim Corporation October 01, 2010BioSpace - Breaking News
Boehringer Ingelheim Corporation Presents New Phase III Data Evaluating Linagliptin in People with Type 2 Diabetes September 22, 2010BioSpace - Breaking News
Boehringer Ingelheim Corporation, Pfizer Inc.'s Spiriva Improves Asthma Treatment, Study Shows September 22, 2010BioSpace - Featured Stories
Boehringer Ingelheim Corporation's Spiriva Improves Asthma Treatment, Study Shows September 22, 2010BioSpace - Featured Stories
Boehringer Ingelheim Presents New Phase III Data Evaluating Linagliptin in People with Type 2 DiabetesSeptember 22, 2010Biotech News - PR Newswire
Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast CancerSeptember 17, 2010Pharma News - Business Wire
Boehringer Ingelheim Corporation Opens ???Centre Of Competence??? Opens As Part Of A ???100m China Plan September 02, 2010BioSpace
Boehringer Ingelheim Corporation Release: Combination Therapy of Telmisartan and Amlodipine Provides Significantly Better Blood Pressure Lowering Than Either Agent Alone August 31, 2010BioSpace - Breaking News
Boehringer Ingelheim Corporation Release: A New Era for Patients with Atrial Fibrillation - Dabigatran Etexilate at the Forefront August 30, 2010BioSpace - Breaking News
Boehringer Ingelheim opens “Center of Competence”in Shanghai as a part of EUR 100 mn expansion project in ChinaAugust 28, 2010Pharmaceutical - Moreover
Boehringer Ingelheim Corporation Opens Center of Competence in Shanghai August 27, 2010BioSpace - Breaking News
FDA Panel To Vet Boehringer Ingelheim Corporation Blood Thinner September 20 August 26, 2010BioSpace
Research and Markets: Boehringer Ingelheim GmbH: PharmaVitae ProfileAugust 17, 2010Pharma News - Business Wire
Boehringer Ingelheim purchases Fort Dodge cattle vaccines for its Mexican businessAugust 12, 2010Pharmaceutical - Moreover
<b>European Committee for Medicinal Products for Human Use (CHMP)</b> Adopts Positive Opinion for TWYNSTA(R), Boehringer Ingelheim Corporation???s New Single Pill Combination Hypertension Treatment July 26, 2010BioSpace - Breaking News
Vitae Pharmaceuticals, Inc. Receives $14 Million Milestone Payment as Boehringer Ingelheim Corporation Advances Lead Compound into Phase I Clinical Trials June 29, 2010BioSpace
Vitae Pharmaceuticals Receives $14 Million Milestone Payment as Boehringer Ingelheim Advances Lead Compound into Phase I Clinical TrialsJune 29, 2010Pharma News - Business Wire
Boehringer Ingelheim launches PCV2 vaccine in RussiaJune 29, 2010Pharma News - PharmiWeb
Boehringer Ingelheim Corporation Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes June 28, 2010BioSpace - Breaking News
Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray against Common ColdJune 28, 2010Pharma News - Business Wire
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 DiabetesJune 26, 2010Pharma News - PR Newswire
Boehringer Ingelheim Announces Results of Phase III Data Showing That Linagliptin Significantly Lowered Blood Glucose with an Excellent Safety and Tolerability ProfileJune 26, 2010Pharma News - Business Wire
Research and Markets: Boehringer Ingelheim in Consumer Health in WorldJune 25, 2010Pharma News - Business Wire
Boehringer Ingelheim Pharmaceuticals, Inc. Comments on June 18th FDA Advisory Committee Meeting June 21, 2010BioSpace - Breaking News
Boehringer Ingelheim Comments on June 18th FDA Advisory Committee MeetingJune 18, 2010Biotech News - PR Newswire
FDA Readies for Fight Over Boehringer Ingelheim Corporation's 'Female Viagra' June 18, 2010BioSpace
Neurocrine Biosciences, Inc., Boehringer Ingelheim Corporation to Develop Diabetes Drug; to Get $10 Million Upfront; up to $225 Million in Milestone Payments June 17, 2010BioSpace
-- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II DiabetesJune 17, 2010Pharma News - PR Newswire
Boehringer Ingelheim Corporation Sex Pill, Flibanserin May Not Aid Women, FDA Staff Say June 16, 2010BioSpace
Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010June 13, 2010Pharma News - PR Newswire
Boehringer Ingelheim: Pipeline, Products, Performance And Potential - New Company Profile PublishedJune 04, 2010Pharmaceutical - Moreover
FDA Considers Endorsement of Boehringer Ingelheim Corporation Drug that Come Call Viagra for Women May 24, 2010BioSpace
NANOBODY(R) LEAD CANDIDATE SELECTED BY BOEHRINGER INGELHEIM FOR DEVELOPMENT IN ALZHEIMER'S DISEASEMay 24, 2010Marketwire - Pharma and Biotech
Boehringer Ingelheim Corporation to Present New Data Regarding Its Investigational Compound BIBW 2992 in Head and Neck Cancer and Non-Small Cell Lung Cancer May 21, 2010BioSpace - Breaking News
Boehringer Ingelheim to Present New Data Regarding Its Investigational Compound BIBW 2992 in Head and Neck Cancer and Non-Small Cell Lung CancerMay 20, 2010Pharma News - PR Newswire
Evotec AG Brings Project in Neuropathic Pain Into Clinical Development in Its Alliance With Boehringer Ingelheim Corporation May 19, 2010BioSpace - Breaking News
Boehringer Ingelheim Corporation Announces New Data on Flibanserin in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder May 19, 2010BioSpace - Breaking News
Boehringer Ingelheim Announces New Data on Flibanserin in Pre-Menopausal Women with Hypoactive Sexual Desire DisorderMay 18, 2010Pharma News - PR Newswire
Pharmaceutical company Boehringer Ingelheim Pharma chooses Kuehne and Nagel for temperature controlled transportMay 12, 2010Pharmaceutical - Moreover
Kuehne + Nagel to transport temperature-controlled shipments for Boehringer Ingelheim to Eastern EuropeMay 11, 2010Pharmaceutical - Moreover
Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE AntibodyMay 05, 2010Biotech News - PR Newswire
AFTER only five months with a hepatitis C nucleoside drug program, leading pharmaceutical company Boehringer Ingelheim has returned it to partner Biota due to a lack of progress on finding a suitable compound.April 26, 2010Pharmaceutical - Moreover
Boehringer Ingelheim grows faster than the pharmaceutical...April 23, 2010Pharmaceutical - Moreover
New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary SchoolsApril 22, 2010Pharma News - PR Newswire
Boehringer Ingelheim Corporation Sees 2010 Sales Flat on Patent Losses April 20, 2010BioSpace
FDA Maintains Essential Use Status of Boehringer Ingelheim Corporation's Combivent(R) (ipratropium bromide and albuterol sulfate) Inhalation Aerosol Through 2013 April 14, 2010BioSpace - Breaking News
New Distribution Agreement With Boehringer Ingelheim Corporation Offers Sigma-Aldrich Corporation Customers Expanded Biodegradable Polylactide Polymers for Biomaterials Research April 08, 2010BioSpace - Breaking News
New Distribution Agreement With Boehringer Ingelheim Offers Sigma-Aldrich Customers Expanded Biodegradable Polylactide Polymers for Biomaterials Research.April 08, 2010Pharma News - PR Newswire
Dalton, Boehringer Ingelheim renew chemistry services agreementApril 07, 2010Pharmaceutical - Moreover
Boehringer Ingelheim Launches Venture Capital FundMarch 31, 2010Biotechnology - Moreover
Boehringer Ingelheim launches €100m corporate venture fundMarch 31, 2010Biotechnology - Moreover
Boehringer Ingelheim launches Global Venture Fund to foster innovation in life sciencesMarch 31, 2010Pharma News - PharmiWeb
Cellectis grants Boehringer Ingelheim license to use homologous recombination patentsMarch 29, 2010Pharmaceutical - Moreover
Boehringer Ingelheim Corporation's Once-Daily MIRAPEX ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease March 23, 2010BioSpace
4-Antibody AG Announces a Long-Term Collaboration With Boehringer Ingelheim Corporation for Therapeutic Antibodies; will Receive Payments of up to EUR 177.5 Million March 16, 2010BioSpace - Breaking News
4-Antibody Announces a Long-Term Collaboration With Boehringer Ingelheim for Therapeutic AntibodiesMarch 16, 2010Pharma News - PharmiWeb
Boehringer Ingelheim's Pradaxa Will Garner Blockbuster Sales of $1.3 Billion by 2018 in the Atrial Fibrillation Drug MarketMarch 01, 2010Medical Pharma - PR Newswire
Biopharmaceuticals: New biopharmaceuticals study findings have been reported by researchers at Boehringer Ingelheim GmbHFebruary 27, 2010Biotechnology - Moreover
Dalton Pharma and Boehringer Ingelheim renew chemistry services agreementFebruary 25, 2010Pharmaceutical - Moreover
Life Sciences: Findings from Boehringer Ingelheim GmbH provide new insights into life sciencesFebruary 25, 2010Pharmaceutical - Moreover
FDA Approves Boehringer Ingelheim Corporation's Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease February 22, 2010BioSpace
Boehringer Ingelheim consolideert wereldwijd webplatform op Day Software CQ5February 18, 2010Pharma News - Business Wire
Boehringer Ingelheim Consolidates Global Web Platform on Day Software CQ5February 18, 2010Pharma News - Business Wire
Boehringer Ingelheim Corporation to Buy Japanese Consumer-Drug Producer for $913 Million February 10, 2010BioSpace
German Boehringer Ingelheim bids for remaining 40% in Japanese SSPFebruary 10, 2010Pharmaceutical - Moreover
Boehringer Ingelheim Corporation to Buy Japanese Consumer-Drug Producer for $913 Million February 10, 2010BioSpace
Tonic Life nets Boehringer Ingelheim lung cancer briefFebruary 04, 2010Pharmaceutical - Moreover
Boehringer Ingelheim and Priaxon Announce a Collaboration to Research and Develop Novel Treatments for CancerJanuary 18, 2010Pharma News - Business Wire
Boehringer Ingelheim und Priaxon geben Zusammenarbeit zur Erforschung und Entwicklung neuartiger Krebstherapien bekanntJanuary 18, 2010Pharma News - Business Wire
Boehringer Ingelheim and Priaxon Ally on Cancer Drug R& DJanuary 18, 2010GEN News Highlights
No Heart Risk Seen with Pfizer Inc. , Boehringer Ingelheim Corporation COPD Drug Says FDA January 15, 2010BioSpace - Breaking News
No Heart Risk Seen with Pfizer Inc., Boehringer Ingelheim Corporation COPD Drug Says FDA January 15, 2010BioSpace
Boehringer Ingelheim's Pramipexole ER Will Garner Peak Year Sales of $250 to $500 Million for the Treatment of Parkinson's DiseaseJanuary 12, 2010Biotech News - PR Newswire
FDA Approves Boehringer Ingelheim Corporation and Pfizer Inc.'s SPIRIVA(R) HandiHaler(R) for the Reduction of COPD Exacerbations December 18, 2009BioSpace - Breaking News
Boehringer Ingelheim initiates first Phase III clinical trial in Ovarian CancerDecember 18, 2009Pharma News - PharmiWeb
FDA Approves Boehringer Ingelheim Corporation and Pfizer Inc.'s SPIRIVA(R) HandiHaler(R) for the Reduction of COPD Exacerbations December 18, 2009BioSpace
Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae ProfileDecember 15, 2009Pharma News - PR Newswire
Boehringer Ingelheim Corporation's New Blood Thinner Could Replace Warfarin to Fight Venous Clots, McMaster University Study December 07, 2009BioSpace



View all the latest news